We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
microRNA deregulation in Hutchinson-Gilford Progeria
© Roll 2015
- Published: 11 November 2015
- Genetic Disease
- Dermal Fibroblast
- Vicious Cycle
- Cellular Model
- Accelerate Aging
The Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disease characterized by an accelerated aging, due to the accumulation in nucleus of a toxic protein called progerin, leading to abnormal gene expression and potential microRNA (miRNA) deregulation. To evaluate the role of miRNAs in HGPS, we conducted an in vitro miRNome analysis by RT-qPCR on dermal fibroblasts of 5 patients and 5 healthy individuals at early (P12+/-2) and for 5 individuals at late passages (P22+/-2). We found 29 deregulated miRNAs in more than 50% of patients (15 overexpressed, 14 underexpressed) presenting different deregulation profiles depending on their age and passage in vitro. We identified 4 interesting potential targeted pathways linked to aging/Progeria: cell cycle and proliferation, senescence, inflammation and autophagy for which 3 miRNAs target central actors of this pathway. No significant difference between patients and controls was detected for 3 autophagy makers on western blotting. However, using flow cytometry, allowing quantification of autophagy level cell by cell, we observed in a 14 yo patient exhibiting the most miRNA deregulated profile, a majority of cells presenting no autophagy. Our hypothesis is that the combined overexpression of the 3 autophagy inhibitor miRNAs acts as a “brake” on autophagy, leading to a decrease of progerin degradation, and finally to a pathophysiological vicious cycle. We are now confirming this hypothesis by transfecting antagomiRs on cellular model. We will also evaluate this mechanism in our HGPS LAKI mouse model and in the context of physiological aging, during which progerin is also produced at lower levels.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.